Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 1, 2010, Pages 3-15

  Bombardieri, E ^a   Coliva, A ^a   Maccauro, M ^a   Seregni, E ^a   Orunesu, E ^a   Chiti, A ^b   Lucignani, G ^c,d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

Author keywords

3 iodobenzylguanidine; Neuroendocrine tumors; Receptors; Somatostatin

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BOC ATE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BZTHI3 OCTREOTATE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DIETHYLDITHIOCARBAMIC ACID OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NOC ATE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE; 5 HYDROXYTRYPTOPHAN; CATECHOLAMINE; DGF F 18; DIETHYLDITHIOCARBAMIC ACID; EDDA TC 99M; EDDA TYROSINE OCTREOTATE; EDDA TYROSINE OCTREOTIDE; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GLUCAGON LIKE PEPTIDE 1 IN 111; HTP C 11; LEVODOPA; LEVODOPA C 11; LEVODOPA F 18; P829 TC 99M; PENTETIC ACID OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE I 123;

ADRENERGIC SYSTEM; ATTENTION; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MEDICAL INFORMATION; METABOLISM; NEUROBLASTOMA; NEUROENDOCRINE SYSTEM; NEUROENDOCRINE TUMOR; ONCOLOGY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; RADIODIAGNOSIS; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR DIAGNOSIS;

DIAGNOSTIC IMAGING; GAMMA RAYS; HUMANS; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN;

EID: 77952506362     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Bombardieri E, Maccauro M, de Deckere E, Savelli G, Chiti A: Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 2001;122:S51-S61. (Pubitemid 33069688)
2. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-247
3. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005;19:265-276 (Pubitemid 40347816)
4. Kurtaran A. Receptor imaging in oncology. In: Aktolun C, Tauxe WN, editors. Nuclear oncology. Springer 1999. p. 333-343
5. Kweekkboom DJ, Krenning EP. Somatostatin receptor imaging in oncology. In: Aktolun C, Tauxe WN, editors. Nuclear oncology. Springer 1999. p. 345-357
6. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumors: biological basis and diagnostic results. Eur J Nucl Med 1998;25:639-658 (Pubitemid 28297840)
7. Maecke HR, Behe M. New octreotide derivates labeled with technetium-99m. J Nucl Med 1996;37:1144.
8. Gabriel M, Muehllechner P, Decristoforo C, von Guggenberg E, Kendler D, Prommegger R et al. 99mTc-EDDA/HYNIC-Tyr(3)-ctreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 2005;49:237-244
9. Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with [111In]-pentetreotide scintigraphy. J Nucl Med 2002;43:889-895
10. Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232-1238 (Pubitemid 30321573)
11. Reubi JC, Schar JC, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282 (Pubitemid 30167697)
12. Ginj M, Chen J, Walter MA et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11:1136-1145 (Pubitemid 40175763)
13. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab 2005;19:213-227
14. Behe M, Behr TM, Schmalor W, Herbst B, Gotthardt M. Indium-111-labeled GLP-1 for in vivo diagnostic of insulinomas. J Nucl Med 2002;43:92P.
15. Kölby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wängberg B, Ahlman H et al. Uptake of metaiodobenzylguanidine in neuroendocirne tumors is mediated by vesicular monoamine transporters. Br J Cancer 2003;89:1383-1388
16. Taïeb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I et al. 18F-FDG avidity of pheochromocitomas and paragangliomas: a new molecular imaging signature? J Nucl Med 2009;50:711-717
17. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med 2009;50:513-519
18. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009;94:1295-1301
19. Neels OC, Koopmans KP, Jager PL, Vercauteren L, van Waarde A, Doorduin J et al. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4- dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res 2008;68:7183-7190
20. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518
21. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30:281-286
22. Westlin JE, Janson ET, Arnberg H, Ahlstrom H, Oberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In]-DTPA-D-Phe1-octreotide. Acta Oncol 1993;32:783-786
23. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF et al. [111In]-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:BP140-BP147
24. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY et al. Somatostatin receptor scintigraphy with [111In]-DTPA-D-Phe1- and 123I-Tyr3 octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
25. McCarthy KE, Wolteeing EA, Anthony LB. In situ radiotherapy with [111In]-pentetreotide. State of the art and persectives. Q J Nucl Med 2000;44:88-95.
26. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with (In-DTPA)octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-122
27. Kaltas GA, Papadogias D, Markas P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005;12:683-699 (Pubitemid 41815771)
28. Arnold R, Goke R, Behr T. Neuroendocrine Gastro-Entero-Pancreatic (GEP) tumours. In: Scheppach W, Bresalier RS, Tytgat GNJ, editors. Gastrointestinal and liver tumors. Berlin: Springer 2004; p. 195-233.
29. Chiti A, Briganti V, Fanti S. Results and potential in neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med 2000;44:42-49
30. Briganti V, Matteini M, Ferri P. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm 2001;16:512-524 (Pubitemid 34024439)
31. Warner RP, O'Dorisio T. Radiolabeled peptides in diagnosis and tumor imaging clinical overview. Semin Nucl Med 2002;32:79-83. (Pubitemid 34311073)
32. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med 2004;48:150-163 (Pubitemid 39248302)
33. Reubi JC. Somatostatin and other peptides receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80:51-6.
34. Schillaci O, Spanu A, Scopinaro F, Falchi A, Danieli R, Marongiu P et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocine tumors. J Nucl Med 2003;44:359-368
35. Schillaci O, Spanu A, Scopinaro F, Falchi A, Corleto V, Danieli R et al. Somatostatin receptor scintigraphy with [111In]-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 2003;23:1687-1695
36. Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun 2004;25:445-449
37. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008;52:323-333
38. Schillaci O. Hybrid SPET/CT: a new for SPET imaging? Eur J Nucl Med Mol Imaging 2005;32:521-524
39. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A et al. SPECT/CT hybrid imaging with [111In]-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol 2003;59:565-73.
40. Ingui CJ, Shah NP, Oates ME. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin Nucl Med 2006;31:665-672
41. Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin Radiolo 2008;63:241-251
42. Wong KK, Cahill JM, Frey KA, Avram AM. Incremental value of [111In]-pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol 2009 Dec 3. [Epub ahead of print].
43. Filippi L, Valentini FB, Gossetti B, Gossetti F, De Vincentis G, Scopinaro F et al. Intraoperative gamma probe detection of head and neck paragangliomas with [111In]-pentetreotide: a pilot study. Tumori 2005;91:173-176
44. Grossrubatscher E, Vignati F, Dalino P, Possa M, Belloni PA, Vanzulli A et al. Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome. J Endocrinol Invest 2005;28:72-78
45. Adams S, Acker P, Lorenz M, Staib-Sebler E, Hör G. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma: a comparison of preoperative and intraoperative tumor localization with histopathologic findings. Cancer 2001;92:263-270 (Pubitemid 32664431)
46. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-58
47. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-247
48. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med 2002;32:92-6.
49. Axelsson R, Herlin G, Bȧȧth M, Aspelin P, Kölbeck KG. Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer. Acta Radiol 2008;49:295-302.
50. Shah T, Kulakiene I, Quigley AM, Warbey VS, Srirajaskanthan R, Toumpanakis C et al. The role of 99mTc-depreotide in the management of neuroendocrine tumours. Nucl Med Commun 2008;29:436-440
51. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med 2002;32:92-6
52. Baath M, Kolbeck KG, Danielsson R. Somatostatin receptor scintigraphy with 99mTc depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Acta Radiol 2004;45:833-839
53. Halley A, Hugentobler A, Icard P, et al. Efficiency of 18F-FDG and 99mTc depreotide SPECT in the diagnosis malignancy of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2005;32:1026-1032
54. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with [111In]-octreotide. J Nucl Med 2000;41:1114-1119 (Pubitemid 30396667)
55. Hubalewska-Dydejczyk A, Fröss-Baron K, MikoΠajczak R, Maecke HR, Huszno B, Pach D etal. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123-1133
56. Papathanasiou ND, Rondogianni PE, Pianou NK, Karampina PA, Vlontzou EA, Datseris IE. 99mTc-depreotide in the evaluation of bone infection and inflammation. Nucl Med Commun. 2008;29:239-46.
57. Pallela VR, Thakur ML, Chakder S, Rattan S. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999;40:352-360 (Pubitemid 29077101)
58. 58.1 Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
59. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q et al. Vasoactive intestinal peptide (VIP) receptor imaging in the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-1121
60. Hessenius C, Bäder M, Meinhold H, Böhmig M, Faiss S, Reubi JC et al. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumors. Eur J Nucl Med 2000;27:1684-1693
61. De Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabelled somatostatin analogues. Acc Chem Res 2009;42:873-880
62. Bernard BF, Béhé M, Breeman WAP, Forrer F, de Blois E, Hoppin J et al. Preclinical evaluation of minigastrin analogs for CCK-B receptor targeting. Cancer Biother & Radiopharm 2003; 18:281.
63. Dorbes S, Mestre-Voegtlé B, Coulais Y, Picard C, Silvente-Poirot S, Poirot M et al. Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting. Eur J Med Chem 2009; Epub ahead of print.
64. Sosabowski JK, Matzow T, Foster JM, Finucane C, Ellison D, Watson SA et al. Targeting of CCK-2 receptor-expressing tumors using a radiolabelled divalent gastrin peptide. J Nucl Med 2009;50:2082-9.
65. McDonald TJ, Jornvall H, Tatemoto K, Mutt V. Identification and characterization of variant forms of the gastrin-releasing peptide (GRP). FEBS Lett 1983;156:349-356
66. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61:786-792
67. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009;94:4398-4405
68. Langer M, La Bella R, Garcia-Garayoa E, Beck-Sickinger AG. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug Chem 2001;12:1028-1034 (Pubitemid 33136875)
69. Zwanziger D, Khan IU, Neundorf I, Sieger S, Lehmann L, Friebe M et al. , Dinkelborg L, Beck-Sickinger AG. Novel chemically modified analogues of neuropeptide Y for tumor targeting. Bioconjug Chem 2008;19:1430-1438
70. Bonnin F, Lumbroso J, Tenebaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-810 (Pubitemid 24151215)
71. Bombardieri E. Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF et al. 123/1231-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imaging 2003;30:BP132-BP139.
72. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-418
73. Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. QJ Nucl Med Mol Imaging 2008;52:419-429
74. Milardovic R, Corssmit EP, Stokkel M. Value of I-MIBG scintigraphy in paraganglioma. Neuroendocrinology 2009; Epub ahead of print.
75. Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. QJ Nucl Med Mol Imaging 2008;52:441-454
76. Troncone L, Rufihi V. MIBG in diagnosis of neuroendocrine tumors. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment (vol 1). Edimburgh: Churchill Livingstone; 2004. p. 83-95.
77. Kaltas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.
78. Castellani MR, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E et al. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 2008;52:430-440
79. Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:388-402.
80. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085-1090
81. Greenblatt DY, Shenker Y, Chen H. The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Ann Surg Oncol 2008;15:900-905
82. Miskulin J, Shulkin BL, Doherty GM, Sisson JC, Burney RE, Gauger PG. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 2003;134:918-922
83. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q J Nucl Med Mol Imaging 2008;52:351-368
84. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26:963-970